

AMENDMENTS TO THE CLAIMS

1. (Currently amended) A method of reduction of the visible signs of fine lines on the skin in an individual in need thereof,

said method comprising contacting the skin of said individual with a composition comprising at least one ACE inhibitor and/or angiotensin II receptor antagonist, or a cosmeceutically acceptable salt thereof,

thereby reducing the visible signs of fine lines on the skin,

wherein the ACE inhibitor and/or angiotensin II receptor antagonist is selected from the group consisting of Alacepril, Delapril, Benazepril, Cilazapril, Captopril, Fosinopril, Lisinopril, Moexipril, Perindopril, Ramipril, Quinapril, Trandolapril, Imidapril, spirapril, temocapril, Enalapril, losartan, valsartan, irbesartan, candesartan, telmisartan, eprosartan, tasosartan, zolarsartan, Zofenapril, Isradipin, Candesartancilexetil, alatriopril, altiopril calcium, ancovenin, hydrochloride benazeprilat, benzazepril, benzoylcaptopril, captopril-cysteine, captoprilglutathione, ceranapril, ceranopril, ceronapril, cilazaprilat, converstatin, delapril-diacid, enalaprilat, enalkiren, enapril, epicaptopril, foroxymithine, fosfenopril, fosenopril, fosenopril sodium, fosinopril sodium, fosinoprilat, fosinoprilic acid, glycopril, hemorphin-4, idapril, indolapril, indolaprilat, libenzapril, lyciumin A, lyciumin B, mixanapril, moexiprilat, moveltipril, muracein A, muracein B, muracein C, perindoprilat, pivalopril, pivopril, quinapril hydrochloride, Pentopril, pentoprilat, quinaprilat, ramiprilat, spirapril hydrochloride, spiraprilat, spiropril hydrochloride, teprotide, trandolaprilat, utibapril, zabicipril, zabiciprilat, olmesartan, medoxomil, zofenoprilat, Asp-Arg-Val-Tyr-Val-His-Pro-Phe; Asn-Arg-Val-Tyr-Val-His-Pro-Phe; Ala-Pro-Gly-Asp-Arg-Ile-Tyr-Val-His-Pro-Phe; Glu-Arg-Val-Tyr-Ile-His-Pro-Phe; Asp-Lys-Val-Tyr-Ile-His-Pro-Phe; Asp-Arg-Ala-Tyr-Ile-His-Pro-Phe; Asp-Arg-Val-Thr-Ile-His-Pro-Phe; Asp-Arg-Val-Tyr-Leu-His-

Pro-Phe; Asp-Arg-Val-Tyr-Ile-Arg-Pro-Phe; Asp-Arg-Val-Tyr-Ile-His-Ala-Phe; Asp-Arg-Val-Tyr-Ile-His-Pro-Tyr; Pro-Arg-Val-Tyr-Ile-His-Pro-Phe; Asp-Arg-Pro-Tyr-Ile-His-Pro-Phe; Asp-Ar-Val-Tyr; 2-Ile-His-Pro-Phe; Asp-Arg-norLeu-Tyr-Ile-His-Pro-Phe; Asp-Arg-Val-Tyr-norLeu-His-Pro-Phe; Asp-Arg-Val-homoSer-Tyr-Ile-His-Pro-Phe; Val-Trp and cosmeceutically acceptable salts thereof.

2. (Canceled)

3. (Currently amended) The method according to claim 2 1, wherein said method is a method of treatment of wrinkles.

4. (Previously presented) The method according to claim 1, wherein said composition comprises at least one ACE inhibitor.

5. (Withdrawn) The method according to claim 4, wherein said ACE inhibitor is a non-thiol-containing ACE inhibitor.

6. (Withdrawn) The method according to claim 4, wherein said ACE inhibitor is a lipophilic ACE inhibitor.

7. (Withdrawn) The method according to claim 4, wherein said ACE inhibitor is an ACE inhibitor binding the zinc-binding ligand of the active site of ACE via a phosphinyl group or a carboxyl group.

8. (Previously presented) The method according to claim 1, wherein said composition comprises at least one angiotensin II receptor antagonist.

9. (Withdrawn) The method according to claim 1, wherein said ACE inhibitor is lisinopril, or a cosmeceutically acceptable salt thereof.

10. (Previously presented) The method according to claim 1, wherein said composition comprises at least two ACE inhibitor(s) and/or angiotensin II receptor antagonist(s).

11. (Previously presented) The method according to claim 1, wherein said ACE inhibitor or angiotensin II receptor antagonist is present in said composition in an amount between about 0.01-100 mg/kg.

12. (Previously presented) The method according to claim 1, wherein said composition further comprises a cosmeceutically-acceptable topical carrier.

13. (Previously presented) The method according to claim 1, wherein said composition is formulated as a cream or lotion.

14. (Previously presented) The method according to claim 1, which comprises repeatedly performing said contacting over an extended period of time.

15. (Previously presented) Method for the treatment of wrinkling, comprising administering an ACE inhibitor and/or angiotensin II receptor antagonist to an individual in need thereof.

16. (Previously presented) The method according to claim 15, wherein said skin ageing or wrinkling is considered premature as compared to normal wrinkling.

17. (Previously presented) The method according to claim 15 wherein the ACE inhibitor and/or angiotensin II receptor antagonist is selected from the group consisting of captopril, enalaprilat and pharmaceutically acceptable salts thereof.

18. (Previously presented) The method according to claim 15, wherein the medicament is in a formulation for topical administration to the skin.

19. (Previously presented) The method according to claim 15, wherein the medicament is administered at least once daily.

20. (Previously presented) The method according to claim 15, wherein the medicament is administered in a concentration equivalent of from 0.01 to 100 mg per kg.

21-22 (Canceled)

23. (Previously presented) The cosmetic method according to claim 1, wherein said ACE inhibitor is captopril, or a cosmeceutically acceptable salt thereof.

24. (Withdrawn) The cosmetic method according to claim 1, wherein said ACE inhibitor is enalaprilat, or a cosmeceutically acceptable salt thereof.

25. (Withdrawn) A composition suitable for application onto skin, consisting of captopril and in the range of 10 to 99.9% by weight of dermatologically acceptable carriers, wherein the carriers are anhydrous.

26. (Withdrawn) A composition suitable for application onto skin, consisting of enalaprilat and in the range of 10 to 99.9% by weight of dermatologically acceptable carriers, wherein the carriers are anhydrous.

27. (Canceled)

28. (Previously presented) The method according to claim 1, wherein the ACE inhibitor and/or angiotensin II receptor antagonist is an ACE inhibitor selected from the group consisting of quinapril, quinaprilat, trandolaprilat, trandolapril, moexipril, moexiprilat, fosinoprilat, fosinopril, benazeprilat, benazepril, enalaprilat, enalapril, captopril, lisinopril, ramaprilat, ramapril and cosmeceutically acceptable salts thereof.